MAP2K7 and metastatic melanoma: Atezolizumab, a PD-L1 inhibitor, received FDA approval in 2020 to be used with cobimetinib (MEK inhibitor) and vemurafenib (BRAF inhibitor) in patients diagnosed with BRAF V600 unresectable or metastatic melanoma.